AU2006238858B2 - Nicotinamide riboside kinase compositions and methods for using the same - Google Patents

Nicotinamide riboside kinase compositions and methods for using the same Download PDF

Info

Publication number
AU2006238858B2
AU2006238858B2 AU2006238858A AU2006238858A AU2006238858B2 AU 2006238858 B2 AU2006238858 B2 AU 2006238858B2 AU 2006238858 A AU2006238858 A AU 2006238858A AU 2006238858 A AU2006238858 A AU 2006238858A AU 2006238858 B2 AU2006238858 B2 AU 2006238858B2
Authority
AU
Australia
Prior art keywords
nicotinamide riboside
nad
nicotinamide
disease
nrk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006238858A
Other languages
English (en)
Other versions
AU2006238858A1 (en
Inventor
Charles M. Brenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of AU2006238858A1 publication Critical patent/AU2006238858A1/en
Application granted granted Critical
Publication of AU2006238858B2 publication Critical patent/AU2006238858B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2006238858A 2005-04-25 2006-04-20 Nicotinamide riboside kinase compositions and methods for using the same Ceased AU2006238858B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/113,701 US20050227327A1 (en) 2004-02-10 2005-04-25 Nicotinamide riboside kinase compositions and methods for using the same
US11/113,701 2005-04-25
PCT/US2006/015495 WO2006116322A2 (en) 2005-04-25 2006-04-20 Nicotinamide riboside kinase compositions and methods for using the same

Publications (2)

Publication Number Publication Date
AU2006238858A1 AU2006238858A1 (en) 2006-11-02
AU2006238858B2 true AU2006238858B2 (en) 2012-11-15

Family

ID=37215374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006238858A Ceased AU2006238858B2 (en) 2005-04-25 2006-04-20 Nicotinamide riboside kinase compositions and methods for using the same

Country Status (6)

Country Link
US (1) US20050227327A1 (https=)
EP (1) EP1877068A4 (https=)
JP (1) JP2008538923A (https=)
AU (1) AU2006238858B2 (https=)
CA (1) CA2609633C (https=)
WO (1) WO2006116322A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20100047177A1 (en) * 2007-01-26 2010-02-25 Washington University Methods and compositions for treating neuropathies
KR101186130B1 (ko) 2010-08-10 2012-09-27 (주)다미화학 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물
CA2951287A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
WO2017004101A1 (en) * 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
KR102114892B1 (ko) 2016-01-11 2020-05-26 더 프록터 앤드 갬블 캄파니 피부 상태의 치료 방법 및 그를 위한 조성물
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
CN106755209B (zh) * 2016-12-29 2021-07-23 苏州汉酶生物技术有限公司 一种酶法制备β-烟酰胺单核苷酸的方法
WO2018237218A1 (en) 2017-06-23 2018-12-27 The Procter & Gamble Company COMPOSITION AND METHOD FOR ENHANCING SKIN APPEARANCE
WO2019108873A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating multiple sclerosis
KR20210011964A (ko) 2018-07-03 2021-02-02 더 프록터 앤드 갬블 캄파니 피부 병태를 치료하는 방법
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN115843238B (zh) 2020-06-01 2025-06-10 宝洁公司 改善维生素b3化合物渗透到皮肤中的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032888A2 (en) * 1999-11-04 2001-05-10 Incyte Genomics, Inc. Human transferase molecules
AU2005211773A1 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
WO2006105403A2 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2006105440A2 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032888A2 (en) * 1999-11-04 2001-05-10 Incyte Genomics, Inc. Human transferase molecules
AU2005211773A1 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
WO2006105403A2 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2006105440A2 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIEGANOWSKI, P. et al.,Cell 2004, vol. 117, pages 495-502 *
LI, J. et al., Journal of Cell Biology 1999, vol. 147, pages 1391-1397 *
SASIAK, K. et al, Archives of Biochemistry and Biophysics, 1996, vol 333, pages 414-418 *
SAUNDERS, P.P. et al, Cancer Res., 1989, vol 49, pages 6593-6599 *

Also Published As

Publication number Publication date
US20050227327A1 (en) 2005-10-13
AU2006238858A1 (en) 2006-11-02
JP2008538923A (ja) 2008-11-13
EP1877068A2 (en) 2008-01-16
EP1877068A4 (en) 2009-01-21
WO2006116322A2 (en) 2006-11-02
WO2006116322A3 (en) 2008-01-17
CA2609633A1 (en) 2006-11-02
CA2609633C (en) 2015-12-01

Similar Documents

Publication Publication Date Title
US8383086B2 (en) Nicotinamide riboside kinase compositions and methods for using the same
AU2006238858B2 (en) Nicotinamide riboside kinase compositions and methods for using the same
Watanabe et al. The first step of glycosylphosphatidylinositol biosynthesis is mediated by a complex of PIG‐A, PIG‐H, PIG‐C and GPI1
Schermer et al. Phosphorylation by casein kinase 2 induces PACS-1 binding of nephrocystin and targeting to cilia
JP3193301B2 (ja) 生理活性タンパク質ｐ１６０
CA2270910A1 (en) Glutathione s-transferase (gst) genes in cancer
Yabu et al. A novel mitochondrial sphingomyelinase in zebrafish cells
Panayiotou et al. Evidence of an intact N-terminal translocation sequence of human mitochondrial adenylate kinase 4
US6511825B1 (en) Cell signaling polypeptides and nucleic acids
CN100390286C (zh) 新酶基因及其表达产物
US20030092116A1 (en) Novel nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and ATPase-like molecules and uses therefor
US6297019B1 (en) Recombinant polynucleotides encoding CYP7 promoter-binding factors
Kobayashi et al. Isoform specific phosphorylation of protein phosphatase 2C expressed in COS7 cells
US20050014692A1 (en) Lactate dehydrogenase as a novel target and reagent for diabetes therapy
JPWO2006054691A1 (ja) 可溶型蛋白質とその利用
CA2329076A1 (en) Human hydrolase homologs: n-terminal asparagine amidohydrolase, glycosyl hydrolase, glucohydrolase, biotinidase, and n-acetylglucosamine 6-p deacetylase
WO2001096575A1 (en) Ceramide kinase and dna encoding the same
WO2003066087A2 (en) Kinases involved in the regulation of energy homeostasis
Yalowitz Identification and characterization of a family of nicotinamide 5'-mononucleotide adenylyltransferases from yeast and humans
US20030175929A1 (en) Recombinant human creatine kinase heterodimer with solution-stability
Gietzen The identification and characterization of casein kinase I epsilon
JP2002330773A (ja) セラミドキナーゼおよびそれをコードするｄｎａ
JPH10191985A (ja) Ｒｈｏ標的プロテインキナーゼｐ１６０の改変タンパク質
JP2007503842A (ja) セラミドキナーゼ様タンパク質
JP2002369684A (ja) ヒトウリジンジホスフェートガラクトース−４−エピメラーゼ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired